Asset Details
Do you wish to reserve the book?
Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study
Do you wish to request the book?
Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study
2018
Overview
Background
Infection by
Staphylococcus aureus (S. aureus)
is a major cause of morbidity and mortality. Colonization by
S. aureus
increases the risk of infection. Little is known about decolonization strategies for
S. aureus
beyond antibiotics, however probiotics represent a promising alternative. A randomized controlled trial was conducted to determine the efficacy of
Lactobacillus rhamnosus
(
L. rhamnosus
) HN001 in reducing carriage of
S. aureus
at multiple body sites.
Methods
One hundred thirteen subjects, positive for
S. aureus
carriage, were recruited from the William S. Middleton Memorial Medical Center, Madison, WI, USA, and randomized by initial site of colonization, either gastrointestinal (GI) or extra-GI, to 4-weeks of oral
L. rhamnosus
HN001 probiotic, or placebo. Nasal, oropharyngeal, and axillary/groin swabs were obtained, and serial blood and fecal samples were collected. Differences in prevalence of
S. aureus
carriage at the end of the 4-weeks of treatment were assessed.
Results
The probiotic and placebo groups were similar in age, gender, and health history at baseline.
S. aureus
colonization within the stool samples of the extra-GI group was 15% lower in the probiotic than placebo group at the endpoint of the trial. Those in the probiotic group compared to the placebo group had 73% reduced odds (OR 0.27, 95% CI 0.07–0.98) of methicillin-susceptible
S. aureus
presence, and 83% reduced odds (OR 0.17, 95% CI 0.04–0.73) of any
S. aureus
presence in the stool sample at endpoint.
Conclusion
Use of daily oral
L. rhamnosus
HN001 reduced odds of carriage of
S. aureus
in the GI tract, however it did not eradicate
S. aureus
from other body sites.
Trial registration
ClinicalTrials.gov Identifier:
NCT01321606
. Registered March 21, 2011.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Analysis
/ Control
/ Female
/ Gastrointestinal Tract - microbiology
/ Healthcare-associated infection control
/ Humans
/ Lacticaseibacillus rhamnosus
/ Male
/ Medicine
/ Methicillin-Resistant Staphylococcus aureus - isolation & purification
/ Methicillin-Resistant Staphylococcus aureus - pathogenicity
/ MRSA
/ Probiotics - therapeutic use
/ Staphylococcal Infections - prevention & control
/ Staphylococcus aureus - isolation & purification
/ Staphylococcus aureus - pathogenicity
/ Staphylococcus aureus infections
/ Veterans
